Stanley E Shackney

20040253738, Dec 16, 2004

Jun 13, 2003

10/461018

Stanley Shackney - Pittsburgh PA, US
Charles Smith - Pittsburgh PA, US
Agnese Pollice - Pittsburgh PA, US
Kathryn Brown - Eighty Four PA, US
Deborah Kociban - Pittsburgh PA, US

Allegheny-Singer Research Institute

G01N033/48

436/063000, 422/073000

An apparatus for correcting for cell aggregates in a cell suspension from patients. The apparatus includes a laser cytometry scanning mechanism for scanning cells of a sample of a cell suspension to obtain data about the samples patients. The apparatus includes a memory for storing the data, the memory in communication with the scanning mechanism patients. The apparatus includes a computer for identifying in the data cell aggregates in the samples from the samples that have been scanned with an APT function, the computer in communication with the memory. A method for correcting for cell aggregates in a cell suspension from patients with an APT function. A method for correcting for cell aggregates in a cell suspension from patients with up to 98.6% accuracy. A computer readable medium.

20070105165, May 10, 2007

Nov 4, 2005

11/267948

Charles Goolsby - Winfield IL, US
T. Shankey - Miami FL, US
David Hedley - Toronto, CA
James Jacobberger - Chesterland OH, US
Stanley Shackney - Pittsburgh PA, US

G01N 33/574

435007230

The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).

20100261204, Oct 14, 2010

Jan 29, 2010

12/696702

Charles GOOLSBY - Winfield IL, US
T. Vincent Shankey - Miami FL, US
David Hedley - Toronto, CA
James Jacobberger - Chesterland OH, US
Stanley Shackney - Pittsburgh PA, US

Beckman Coulter, Inc. - Brea CA

G01N 33/574

435 723

The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).

20120028907, Feb 2, 2012

Nov 13, 2009

13/126023

Stanley E. Shackney - Pittsburgh PA, US

Intelligent Oncotherapeutics, Inc. - Pittsburgh PA

A61K 38/17
C07D 403/14
A61K 31/506
C07F 9/6512
A61K 31/675
C07D 401/12
A61K 31/454
C07D 413/12
A61K 31/5377
C07D 487/04
A61K 31/55
C07D 403/04
A61K 31/497
C07K 14/47
C07C 43/23
A61K 31/085
C40B 60/12
A61P 35/00
G06F 19/00
C40B 30/04

514 192, 506 9, 544295, 51425219, 544244, 514 80, 546201, 514323, 544119, 5142345, 540578, 514215, 544405, 51425505, 530324, 568652, 514720, 530350, 506 39, 702 19

The disclosure relates to methods for identifying a tumor as an E2F-responsive gene over-expressing (ERGO) tumor, methods of determining the likelihood that an ERGO tumor patient will survive to a future date, methods of treating an ERGO tumor in a patient, and methods of selecting patients diagnosed as ERGO tumor prostate cancer patients for aggressive clinical treatment. The methods of the disclosure are applicable to ERGO tumors present in different human organs and tissues such as breast, lung, thyroid, ovary, and prostate.